RxDoctor Payments Data

Michael Siegel, MD

Dermatology · Waterford, MINPI 1104915875

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $598,153 of the $708,469 with a category attached, or 84.4%. 39 manufacturers reported payments, led by Lilly USA, LLC at 30.6% of the total. Among dermatology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$708,469in general payments, 2019–2025

Across 1,696 payments — averaging $417.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$217K
  • AbbVie$117K
  • UCB, Inc.$103K
  • Johnson & Johnson$65K
  • Janssen Scientific Affairs, LLC$59K
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$33K
  • plus $114K from 33 others

What the payments were for

  • Consulting fees$40,2876%
  • Speaking & faculty fees$598,15384%
  • Travel & lodging$34,8735%
  • Food & beverage$34,3575%
  • Education$8000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$708,469 in reported general payments places this provider in the 95th percentile of 404 dermatology providers in Michigan.

See all dermatology providers in Michigan

Medicare billing

Part B allowed, 2024
$317,889
Medicare patients
878
Services billed
5,377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa25$518,678
Cosentyx Unoready PenSecukinumab46$447,080
StelaraUstekinumab18$418,888
Humira(Cf) PenAdalimumab33$255,967
Cosentyx Sensoready (2 Pens)Secukinumab27$254,722
Dupixent PenDupilumab57$208,585
TremfyaGuselkumab15$199,572
Enbrel SureclickEtanercept15$110,394
Dupixent SyringeDupilumab27$102,454
AdbryTralokinumab-Ldrm18$71,798
OtezlaApremilast14$65,596
XolairOmalizumab12$33,329
Betamethasone Dipropionate192$6,220
Clobetasol Propionate187$5,188
Triamcinolone Acetonide336$4,314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Tremfya$64,884$618,46033 claims
LEO Pharma Inc.Adbry$3,979$71,79818 claims
AmgenOtezla$476$65,59614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 404 dermatology providers in Michigan.

Other dermatology in Waterford

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →